ALD-1010

N/A

Report date: 2025/01/26 17:49:04
NME

Base Information

Drug NameALD-1010
Drug Alias Nameadult chronic myelocytic leukemiat herapy (Allcron Pharma)Bcr-Abl T315I drug resistance therapy (Allcron Pharma)ALD-1010
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBcr-Abl tyrosine kinase inhibitors
TargetsBcr-Abl tyrosine kinase
Therapy Area/IndicationsLeukemia, Myelogenous, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTherapy Architects LLC
China Registration ClassN/A

Develop Information

Active CompaniesTherapy Architects LLC
Inactive CompaniesAllcron Pharma Inc
Active IndicationsLeukemia, Myelogenous, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A